FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.98
-0.02 (-0.13%)
As of 12:05PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close16.00
Open15.93
Bid15.97 x 100
Ask15.98 x 200
Day's Range15.78 - 16.01
52 Week Range11.44 - 17.62
Volume230,066
Avg. Volume2,235,604
Market Cap3.012B
Beta1.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • All You Need To Know About Amicus Therapeutics Inc’s (NASDAQ:FOLD) Financial Health
    Simply Wall St.26 days ago

    All You Need To Know About Amicus Therapeutics Inc’s (NASDAQ:FOLD) Financial Health

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Amicus Therapeutics Inc (NASDAQ:FOLD), with a market capitalization of US$2.89b, rarely draw their attention from the investingRead More...

  • Benzinga26 days ago

    Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FOLD earnings conference call or presentation 8-May-18 12:30pm GMT

    Q1 2018 Amicus Therapeutics Inc Earnings Call

  • When Can We Expect A Profit From Amicus Therapeutics Inc (NASDAQ:FOLD)?
    Simply Wall St.2 months ago

    When Can We Expect A Profit From Amicus Therapeutics Inc (NASDAQ:FOLD)?

    Amicus Therapeutics Inc’s (NASDAQ:FOLD): Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The US$2.68B market-cap company announcedRead More...

  • Associated Press2 months ago

    Amicus Therapeutics: 1Q Earnings Snapshot

    The Cranbury, New Jersey-based company said it had a loss of 28 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...

  • Analyzing the Financial Performance of Amicus Therapeutics
    Market Realist3 months ago

    Analyzing the Financial Performance of Amicus Therapeutics

    Amicus Therapeutics (FOLD) generated net product sales of $36.9 million in 2017 compared to $4.9 million in 2016. For 2018, 2019 and 2020, Amicus is expected to generate revenues of $85.3 million, $180.2 million, and $255.6 million, respectively, on the back of new geographic approvals and Galafold’s market penetration. Amicus incurred a cost of goods sold of $833,000 in 2016 compared to $6.2 million in 2017.

  • Analyzing the Market Potential for Amicus’s Galafold
    Market Realist3 months ago

    Analyzing the Market Potential for Amicus’s Galafold

    According to the American Journal of Human Genetics, newborn screening studies in Italy, Taiwan, and Austria found the incidence of Fabry disease mutations to be between 1:2,400 and 1:4,000—more than ten times higher than previous studies. At present, Galafold has two competitors: agalsidase beta and agalsidase alfa.

  • Exploring Amicus Therapeutics’ Promising Research Pipeline
    Market Realist3 months ago

    Exploring Amicus Therapeutics’ Promising Research Pipeline

    Amicus Therapeutics (FOLD) is currently developing a novel proprietary enzyme replacement therapy (or ERT) coformulated with migalastat HC1 for Fabry disease patients with nonamenable genetic mutations. The therapy is currently in late preclinical development. The future value driver of the company’s research pipeline is ATB200/AT2221, a novel, late-stage treatment for Pompe disease.

  • Analysts’ Ratings for Amicus and Its Peers in April
    Market Realist3 months ago

    Analysts’ Ratings for Amicus and Its Peers in April

    Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.

  • Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options

    Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.

  • Analyst Ratings for UniQure and Its Peers in April 2018
    Market Realist3 months ago

    Analyst Ratings for UniQure and Its Peers in April 2018

    UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.

  • Analysts Rate Voyager Therapeutics and Its Peers in April
    Market Realist3 months ago

    Analysts Rate Voyager Therapeutics and Its Peers in April

    Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.

  • Why Amicus Therapeutics Stock Rose in the Week Ended March 29
    Market Realist4 months ago

    Why Amicus Therapeutics Stock Rose in the Week Ended March 29

    A Look at Pharma's Gainers in the Week Ended March 29

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of FOLD earnings conference call or presentation 28-Feb-18 1:30pm GMT

    Q4 2017 Amicus Therapeutics Inc Earnings Call

  • Benzinga5 months ago

    The Week Ahead In Biotech: Earnings, PDUFA Dates And More

    The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...

  • Best Growth Stock in January
    Simply Wall St.6 months ago

    Best Growth Stock in January

    Athenex and Amicus Therapeutics are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the future outlookRead More...

  • TheStreet.com6 months ago

    2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

    Outside of oncology, the rare disease area is a good target for M&A in 2018.

  • Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher
    Zacks6 months ago

    Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher

    Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • January Growth Opportunities – Athenex And More
    Simply Wall St.7 months ago

    January Growth Opportunities – Athenex And More

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...

  • Investopedia7 months ago

    3 Small Biotechs With Big Upside

    Biotech stocks have broken out and in some cases could be set to rise sharply over the next few months.

  • Capital Cube7 months ago

    ETFs with exposure to Amicus Therapeutics, Inc. : December 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amicus Therapeutics, Inc. Here are 5 ETFs with the largest exposure to FOLD-US. Comparing the performance and risk of Amicus Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • This Tiny Biotech Pins Hope on U.S. Approval
    Motley Fool7 months ago

    This Tiny Biotech Pins Hope on U.S. Approval

    A new treatment of Fabry disease could be available in the United States as soon as 2018.

  • Lincoln National, Sears, Hasbro, Steris & Amicus Therapeu...
    CNBC Videos6 months ago

    Lincoln National, Sears, Hasbro, Steris & Amicus Therapeu...

    The "Halftime Report" traders give their top stocks to watch for the second half.